Article Information
History
- May 20, 2021.
Article Versions
- Version 1 (May 15, 2021 - 14:36).
- Version 2 (May 16, 2021 - 23:12).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Madhumita Shrotri1,2,
- Ellen Fragaszy1,4,
- Cyril Geismar1,
- Vincent Nguyen1,
- Sarah Beale1,3,
- Isobel Braithwaite1,
- Thomas E Byrne1,
- Wing Lam Erica Fong1,
- Jana Kovar3,
- Annalan M D Navaratnam1,
- Parth Patel1,
- Anna Aryee1,
- Jamie Lopez Bernal2,
- Anne M Johnson5,
- Alison Rodger5,
- Andrew C Hayward3 and
- Robert W Aldridge1,*
- 1Institute of Health Informatics, University College London, UK
- 2Public Health England
- 3Institute of Epidemiology and Health Care, University College London, London, UK
- 4Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK
- 5Institute for Global Health, University College London, London, UK
- ↵*Correspondence to: Prof Robert W Aldridge, r.aldridge{at}ucl.ac.uk
- 1Centre for Behaviour Change, University College London, London, UK
- 2Department of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK
- 3Francis Crick Institute, London, UK
- 4Health Protection and Influenza Research Group, Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK
- 5University College London Hospital, London, UK
- 6Department of Computer Science, University College London, London, UK
- 7London Centre for Nanotechnology and Division of Medicine, London, University College London
- 8SpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UK
- 9Institute for Global Health, University College London, London, UK
Posted May 20, 2021.
Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study)
